Trial · NCT07283562
Gastrodin Acupoint Injection for Sensorineural Hearing Loss With Vertigo
NCT07283562, Not applicable, Completed, The First Hospital of Hebei Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Gastrodin Acupoint Injection for Sensorineural Hearing Loss With Vertigo. Trials, record NCT07283562. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07283562
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Gastrodin Acupoint Injection for Sensorineural Hearing Loss With Vertigo
- NCT number
- NCT07283562
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 100 participants, actual
- Lead sponsor
- The First Hospital of Hebei Medical University
- Conditions
- Sensorineural Hearing Loss, Vertigo
- Interventions
- Gastrodin Injection, Conventional Therapy
- First posted
- 2025-12-16
- Last updated
- 2025-12-16
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Pure Tone Average (PTA) | Baseline and Week 4 | Calculated as the average of air-conduction hearing thresholds at 0.5, 1, 2, and 4 kHz measured by audiometry. |
| Primary | Change in Dizziness Handicap Inventory (DHI) Score | Baseline and Week 4 | The DHI is a 25-item self-assessment questionnaire evaluating the functional, emotional, and physical impact of dizziness. The total score ranges from 0 to 100. Higher scores indicate greater perceived handicap and more severe dizziness symptoms. |
| Secondary | Change in Word Recognition Score (WRS) | Baseline and Week 4 | WRS assesses speech discrimination ability by measuring the percentage of words correctly identified from a phonetically balanced list at a comfortable listening level (40 dB above speech reception threshold). Scores range from 0% to 100%. Higher scores indicate better hearing function and speech understanding. |
| Secondary | Change in Tinnitus Evaluation Questionnaire (TEQ) Score | Baseline and Week 4 | The TEQ is used to assess the severity and impact of tinnitus on daily life. The questionnaire consists of items related to tinnitus characteristics and patient distress. Higher total scores indicate more severe tinnitus symptoms and a greater negative impact on the patient. |
| Secondary | Change in Hamilton Anxiety Scale (HAMA) Score | Baseline and Week 4 | The HAMA is a clinician-rated scale to measure the severity of anxiety symptoms. It consists of 14 items, each scored from 0 to 4. The total score ranges from 0 to 56, with higher scores indicating more severe anxiety. |
| Secondary | Change in Hamilton Depression Scale (HAMD) Score | Baseline and Week 4 | The HAMD is a clinician-rated scale to measure the severity of depressive symptoms. It contains 17 or 24 items (depending on version used), with higher total scores indicating more severe depression. |
| Secondary | Change in Mean Flow Velocity (Vm) of Middle Cerebral Artery | Baseline and Week 4 | Vm is measured using Transcranial Doppler (TCD) ultrasound in the middle cerebral artery. Measured in cm/s. In the context of ischemic pathology, an increase in Vm (within normal ranges) indicates improved cerebral blood perfusion. |
| Secondary | Change in Pulsatility Index (PI) of Middle Cerebral Artery | Baseline and Week 4 | PI is a hemodynamic parameter measured using Transcranial Doppler (TCD) calculated as (Systolic Velocity - Diastolic Velocity) / Mean Velocity. It reflects downstream vascular resistance. A lower PI score indicates reduced vascular resistance and improved microcirculation. |
| Secondary | Change in Serum Endothelin-1 (ET-1) Level | Baseline and Week 4 | Measurement of serum ET-1 levels via enzyme-linked immunosorbent assay (ELISA). ET-1 is a potent vasoconstrictor. Lower levels indicate reduced vasoconstriction and potentially improved microcirculation. |
| Secondary | Change in Serum Nitric Oxide (NO) Level | Baseline and Week 4 | Measurement of serum NO levels via enzyme-linked immunosorbent assay (ELISA). NO is a vasodilator. Higher levels indicate improved vasodilation and endothelial function. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07283562
GET https://conductscience.org/api/trials/v1/NCT07283562/registered